Active surveillance for prostate cancer: a narrative review of clinical guidelines

Key Points A number of guidelines have been published that include criteria for active surveillance (AS) enrolment and subsequent management to assist clinicians and patients in critically important treatment related decision-making Consensus on inclusion criteria, surveillance schedules and intervention thresholds is currently lacking The future of AS and its uptake as a management modality will depend on better patient selection and validated monitoring schedules to improve identification of disease progression Combining existing evidence and gathering more long-term evidence is needed to derive a broadly supported guideline to reduce variations in clinical practice and to optimize clinical decision-making